(Q38134412)

29 August 2017

title

Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation (English)

1 reference

29 August 2017

main subject

irritable bowel syndrome

1 reference

Robin D Rothstein

1

1 reference

29 August 2017

Frank K Friedenberg

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

5 September 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

15

1 reference

29 August 2017

page(s)

2125-2132

1 reference

Epidemiology of constipation in North America: a systematic review

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Resource utilization associated with irritable bowel syndrome in the United States 1987-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Chronic constipation: new diagnostic and treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Pilot study on the effect of linaclotide in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Efficacy of linaclotide for patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Two randomized trials of linaclotide for chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.833605

10.1517/14656566.2013.833605

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference